Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.46 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | LIG1 | P18858 | 1/20 | 0.40 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7688021 | 0.91 | MAPT (0.63) | BRD4GAAMAPTKDM1AKCNH2 | |
| SCHEMBL2046091 | 0.83 | ESR2 (0.50) | BRD4GAAMAPTKDM1AKCNH2 | |
| SCHEMBL2046094 | 0.83 | ESR2 (0.50) | BRD4GAAMAPTKDM1AKCNH2 | |
| SCHEMBL2047764 | 0.83 | ESR2 (0.50) | BRD4GAAMAPTKDM1AKCNH2 | |
| SCHEMBL657720 | 0.80 | BRD4 (0.49) | BRD4GAAMAPTKDM1AKCNH2 | |
| SCHEMBL1673541 | 0.80 | LMNA (0.49) | BRD4GAAMAPTKDM1AKCNH2 | |
| SCHEMBL17996691 | 0.80 | ESR2 (0.50) | BRD4GAAMAPTKDM1AKCNH2 | |
| SCHEMBL6660756 | 0.77 | ESR2 (0.64) | BRD4GAAKDM1AKCNH2MAOB | |
| SCHEMBL10672428 | 0.77 | MAPT (0.77) | BRD4GAAMAPTMEN1KMT2A | |
| SCHEMBL426339 | 0.76 | MAP1LC3B (0.53) | GAAMAPTKDM1AMAOBLIG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103887-A1 | PROLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 北京康辰药业股份有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-12612408-B2 | Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20260049092-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4087836-B1 | PROCESSES FOR PREPARING TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | CANTERO THERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4568955-A1 | ANTIBACTERIAL COMPOUNDS | Blacksmith Medicines, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119907795-A | Antibacterial compounds | 布莱克史密斯医药公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-114945559-B | Preparation method of triazole glycollic acid oxidase inhibitor | 坎特罗治疗有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119585251-A | Heterocyclic derivative, composition and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2024240242-A1 | COMPOUND CONTAINING AMIDE-SUBSTITUTED AROMATIC RING, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 正大天晴药业集团股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| US-20240366770-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| EP-1991544-A2 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS | Transtech Pharma, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20080251761-A1 | Spiro[3.3] Heptyl-Dioxan Derivatives and Their Use in Liquid Crystal Media | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080251761-A1 | Spiro[3.3] Heptyl-Dioxan Derivatives and Their Use in Liquid Crystal Media | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1921065-A1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1888523-A2 | CYCLOBUTYL AMINE DERIVATIVES | Abbott Laboratories (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070191385-A1 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | VTV THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2007089857-A2 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007045382-A1 | SPIRO [3.3] HEPTYL-DIOXAN DERIVATIVES AND THEIR USE IN LIQUID CRYSTAL MEDIA | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078133-A1 | Cyclobutyl amine derivatives | ABBVIE INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2006132914-A2 | CYCLOBUTYL AMINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049092-A1 | ANTIBACTERIAL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, FPR1 | BRD4 1272/4885GAA 3838/4885MAPT 4789/4885 |
| US-20070191385-A1 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | PTP4A1, PTPRJ, PTP4A2 | BRD4 1556/4885GAA 190/4885MAPT 3556/4885 |
| US-20240366770-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | BRD4 537/4885GAA 2167/4885MAPT 3793/4885 |
| US-20070078133-A1 | Cyclobutyl amine derivatives | HRH2, HRH4, HRH3 | BRD4 1615/4885GAA 1013/4885MAPT 2084/4885 |
| US-12612408-B2 | Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof | WEE1, WEE2, TK1 | BRD4 2330/4885GAA 3293/4885MAPT 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.